Belite Bio (BLTE) Common Equity (2020 - 2025)

Belite Bio has reported Common Equity for 6 years, with the latest figure at $770.5 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 428.38% year-over-year to $770.5 million; the trailing twelve-month figure through Dec 2025 stood at $770.5 million (up 428.38% YoY), and the FY2025 full-year result was $770.5 million, up 428.38% from the prior year.
• Common Equity for Q4 2025 stood at $770.5 million, up from $145.8 million in the prior quarter.
• The five-year high for Common Equity was $770.5 million in Q4 2025, with the low at -$15.1 million in Q4 2021.
• Average Common Equity over 5 years is $206.6 million, with a median of $90.4 million recorded in 2023.
• Year-over-year, Common Equity plunged 114.48% in 2021 and jumped 428.38% in 2025.
• Tracing BLTE's Common Equity over 5 years: stood at -$15.1 million in 2021, then jumped by 374.97% to $41.5 million in 2022, then soared by 117.9% to $90.4 million in 2023, then jumped by 61.25% to $145.8 million in 2024, then jumped by 428.38% to $770.5 million in 2025.
• The last three Common Equity figures came in at $770.5 million (Q4 2025), $145.8 million (Q4 2024), and $90.4 million (Q4 2023), per Business Quant data.

Peer Comparison